SFSoroush Fariman

Soroush Fariman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soroush Fariman has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparing Outcomes: In-Person and Telehealth Oncology Visits

    by Ilona Fridman, Christine Neslund-Dudas, Lauren Jordan Barrow, Matthew R. Dunn, Regina Jones, Alan C. Kinlaw, Angela B. Smith, Jacob N. Stein, Samantha Tam, William A. Wood, et al.

    PURPOSE: Telemedicine offers significant benefits, but concerns regarding care quality persist. To inform future oncology telehealth policy, we compared subsequent health care use, patient-reported care quality, and communication outcomes between telehealth and in-person visits. METHODS: An observational cohort study (April 2022-October 2023) included patients age 21+ years with malignant neoplasms, a scheduled oncology visit, and cancer treatment initiated 6 months to 3 years before the study. Black adults and those with telehealth visits were oversampled. Pre- and post-visit telephone survey data were joined with electronic health record data and geocoded community characteristics. Outcomes included subsequent acute care events (emergency department visits and unplanned hospitalizations), follow-up visits, patient perceptions of whether their care needs were met, and communication quality via validated instruments, with Likert-scale responses. We estimated prevalence differences (PDs) in outcomes by visit type using propensity score–weighted generalized linear models that adjusted for patient socioeconomic, health, and census tract–level differences. RESULTS: After propensity score adjustments achieved covariate balance, 487 respondents (93 telehealth, 394 in-person) were included. Mean age was 64 (standard deviation = 13) years; 62% were female, 26% were Black, 82% had some college degree or more, and 25% reported fair/poor health. Follow-up in-person visits at 30 days were more frequent after telehealth (64%, 46%; PD = 0.18 [95% CI, 0.07 to 0.28]), with no differences at 7 or 14 days. Acute care use did not significantly differ at any time point. Quality and communication ratings were similar (PD range: 0.00-0.09), except for perceived privacy: 80% in-person, 67% telehealth, P < .01. CONCLUSION: Although mostly similar health care use and patient perceptions suggest telehealth as a viable oncology option, identified differences highlight the need to ensure privacy and evaluate when telehealth visits are most appropriate.


  • Open Access

    An umbrella review of patient-reported shared decision-making instruments: Developing a contemporary model of the shared decision-making process

    by Soroush Fariman, Amy M. Barrett, Sarah T. Hawley, Kenneth Resnicow, Angela M. Stover, Mian Wang, Marilyn Schapira, Jennifer Elston Lafata


  • Acute Care Events During Systemic Cancer Treatment: Moving From Risk Prediction to Clinical Decision Support Using a Two-Model Approach

    by Jacob Newton Stein, Soroush Fariman, Yishu Zhang, Bahjat Qaqish, Jennifer Elston Lafata

    PURPOSE: Acute care events (ACEs, emergency department visits and hospitalizations) are burdensome among patients with cancer—many are preventable. Prognostic risk models have not been consistently deployed as a preventive strategy. We convened a Clinical Advisory Panel (CAP) to address this translational bottleneck and develop clinically and statistically valid prognostic models to enable risk-stratified intervention. METHODS: We identified patients age 21+ years initiating cancer treatment at an academic center or affiliated sites. We extracted sociodemographic and clinical information from the EHR. Data were divided into training (50%), validation (25%), and test (25%) sets. Models were developed using constrained elastic-net logistic regression, with clinically informed coefficient constraints. RESULTS: In all, 4,697 patients were included, the mean age was 64 years, 71.9% were White, 21.8% had GI cancers, 21.7% had hematologic malignancies, 46.0% were Medicare insured, 77.6% were receiving chemotherapy, and 25.4% were receiving immunotherapy. We developed two models with our CAP, a baseline model predicting risk using a planned anticancer regimen and a follow-up model updating with drug dispensing and clinical changes. ACE in the previous month was the strongest predictor in both models (odds ratio [OR], 1.5, baseline model), with chemotherapy receipt (OR, 1.18), heart failure (OR, 1.22), abnormal international normalized ratio (OR, 1.30), and late-stage cancer (OR, 1.20) contributing. Both had acceptable statistical performance (C-statistic 0.71 and 0.70) and identified patients at the highest risk for ACE. CONCLUSION: We present a novel approach to ACE prediction among patients receiving cancer treatment using two models to anticipate patients' risk before treatment starts and then update based on clinical trajectory, facilitated by engagement of a CAP. To prevent ACE, risk-stratified interventions should focus on the factors we observed—optimizing comorbidities, proactively managing symptoms from high-toxicity regimens, or advanced disease.

  • Open Access

    End-of-Life and Palliative Care Disparities Among American Indians and Alaska Natives with Cancer: A Scoping Review

    by Soroush Fariman, Joel Begay, Linda Burhansstipanov, Marc A. Emerson, Stephanie B. Wheeler, Jennifer Elston Lafata, Ronny A. Bell

    Purpose: To identify disparities in access, utilization, and quality of end-of-life (EOL) and palliative care services for American Indians and Alaska Natives (AIAN) with cancer in the US. Methods: Systematic searches were conducted in PubMed/MEDLINE, Embase, and Scopus. English-language original research studies reporting any quantitative estimates of measures of care quality or utilization for EOL and palliative care for AIAN individuals with cancer compared to other races were included (2014-2025). Screening and data extraction were conducted by two independent reviewers and discrepancies were resolved through consensus. Findings were synthesized through iterative team discussions. Results: Of 1693 unique records, 153 underwent full-text review, and 22 met inclusion criteria. Considerable heterogeneities were observed in EOL care outcomes and covariates included in multivariable regression models assessing disparities: Compared to White individuals, AIAN individuals with cancer had significantly lower in-home or hospice and higher medical facility deaths (9/11 studies); higher acute care use (3/4 studies); lower hospice use (2/4 studies); lower anxiolytic medication use (1/1 study); and higher receipt of any palliative treatment (3/6 studies); but no differences in late hospice initiation (0/3 studies); or aggressive treatment near the EOL period (0/6 studies). Conclusions: AIAN individuals with cancer appear more likely to experience a medicalized death. Mechanisms underlying these disparities remain poorly understood. Future studies should provide greater clarity in analytical methods to improve interpretability of disparities measures, use more consistent measures of EOL care quality, explore within-AIAN variation such as regional, tribal, and rural–urban differences, as well as cultural implications for the delivery of appropriate EOL care.

  • Association of Patient-Provider Race/Ethnicity Concordance and Patient-Reported Shared Decision Making Among US Adults: A National Study, 2015–2021

    by Soroush Fariman, Adel Ahmadi, Justin G. Trogdon, Lorinda A. Coombs, Jennifer Elston Lafata

    Background Shared decision making (SDM) is central to ethical, patient-centered care and has been linked to improved patient outcomes. Racial/ethnic disparities in SDM may contribute to health outcome inequities. The relationship between patient-provider race/ethnicity concordance and patient perceptions of SDM in routine care is less well known. Objective To examine the association between patient–provider race/ethnicity concordance and patient-perceived SDM among a nationally representative sample of US adults. Design Cross-sectional analysis of nationally representative Medical Expenditure Panel Survey data 2015–2021. Subjects Adults (≥ 18 years, N = 23,790) from the Medical Expenditure Panel Survey (2015–2021; excluding 2018 and 2020 that did not include all SDM questions), who reported having a person (rather than a clinic or group) as their usual source of care provider were included. The sample included Non-Hispanic White (NHW; n = 15,738), Non-Hispanic Black (NHB; n = 3337), Hispanic (n = 3352), and Non-Hispanic Asian (NHA; n = 1363) respondents. Main Measures The primary exposure was patient–provider race/ethnicity concordance, as measured by respondents’ self-identified race/ethnicity and perceived race/ethnicity for their provider. The primary outcome was patient-reported SDM as measured by seven question items and dichotomized to high vs. low scores. Multivariable logistic regressions controlled for patient-level (sociodemographic, language, country of birth, and perceived health status), provider-level (gender, provider type), census region, and survey year fixed effects. Key Results Overall, 29.4% of the sample reported high SDM. Race/ethnicity concordance was positively associated with patient perception of high SDM among NHB (adjusted odds ratio [aOR], 1.23; 95% CI, 1.03–1.47) and NHW adults (aOR, 1.20; 95% CI, 1.09–1.32). No significant associations were observed for NHA and Hispanic adults. Conclusions Patient–provider race/ethnicity concordance was significantly associated with improved patient perception of SDM quality among NHW and NHB adults. Findings highlight the importance of addressing structural and interpersonal factors to foster effective and equitable SDM experiences among diverse populations.


  • Open Access

    Real-World Determinants of Olanzapine Prescribing for Antiemetic Prophylaxis in Adults Receiving Highly-Emetogenic Chemotherapy

    by Soroush Fariman, Haneul Gil, Kevin Chen, Jacob N. Stein, Jennifer Elston Lafata

    Background: Since 2017, guidelines recommend a four-drug prophylactic antiemetic regimen—5HT3 receptor antagonist (5HT3RA), NK1 receptor antagonist (NK1RA), dexamethasone, and olanzapine—for patients receiving highly emetogenic chemotherapy (HEC). This study examines prophylactic olanzapine prescribing in patients initiating HEC and associated sociodemographic, clinical, and contextual factors. Methods: A retrospective cohort study was conducted using electronic health record data from an academic cancer center and affiliated community practices across the state of North Carolina, joined with geocoded community factors. Adults ≥21 years initiating cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, or cyclophosphamide plus anthracycline (AC) in 2022 were included. Antiemetic orders placed before HEC administration were classified as three-drug (5HT3RA, NK1RA, dexamethasone) or four-drug (plus olanzapine). Late olanzapine use (within 30 days post-HEC) was also assessed. Multivariable logistic regression evaluated factors associated with regimen type. Results: Among 878 patients, all received orders for the three-drug regimen, but only 300 (34.2%) had olanzapine ordered within 30 days before first HEC. After adjusting for covariates, olanzapine prescribing was less likely in patients with breast (OR = 0.13, 95%CI = 0.07-0.23), gastrointestinal (OR = 0.20, 95%CI = 0.04-0.94), gynecological (OR = 0.14, 95%CI = 0.03-0.69), and head and neck (OR = 0.17, 95%CI = 0.05-0.66) compared to hematological cancers, in those receiving cisplatin (OR = 0.20, 95%CI = 0.06-0.70) and carmustine (OR = 0.02, 95%CI = 0.00-0.48) compared to AC, and in community (OR = 0.40, 95%CI = 0.27-0.61) versus academic settings. Prescribing was also lower among patients residing in low- (OR = 0.49, 95%CI = 0.25-0.93) or lower-middle income (OR = 0.50, 95%CI = 0.32-0.78) areas, but higher among those living >6 miles from treatment facilities (OR = 1.95, 95%CI = 1.08-3.58). Among patients without prophylactic olanzapine, 12.5% were prescribed it within 1 to 30 days post-HEC. Conclusions: Despite guideline recommendations, prophylactic olanzapine use in HEC remains suboptimal, influenced by clinical and non-clinical contextual factors. Targeted efforts at information dissemination and updated prescribing systems are needed to promote equitable, evidence-based supportive care.


  • Evaluation of End-of-Life Quality Care Between American Indian and White North Carolina Decedents Diagnosed With Lung Cancer, 2003-2020

    by Bradford E. Jackson, Chris D. Baggett, Lisa P. Spees, Daniel Carrizosa, Marc A. Emerson, Soroush Fariman, Ana I. Salas, Ronny A. Bell, Stephanie B. Wheeler

    PURPOSE: Lung cancer mortality rates for American Indians (AIs) are the highest among US race groups. End-of-life (EOL) care presents opportunities to limit aggressive and potentially unnecessary treatment. We evaluated differences in EOL quality of care between AI and White (WH) decedents with lung cancer. METHODS: Our cohort included adult AI and WH decedents diagnosed with lung cancer (2003-2020) in North Carolina, who had health insurance claims during the month of and the month preceding death. EOL outcomes assessed during the last 30 days of life included intravenous chemotherapy, hospital admission, hospice initiation, ICU admission, >one emergency department (ED) visit, and in-hospital death. We used Poisson regression models to estimate risk ratios (RRs) and 95% CLs for each outcome comparing AI with WH, adjusting for rural/urban residence, age at diagnosis, insurance status, sex, histology, and diagnosis year. We also evaluated associations in the metastatic lung cancer subcohort. RESULTS: Our cohort comprised 594 AI and 49,296 WH decedents. Compared with WH decedents, AIs were younger at diagnosis (66 v 71 years), more frequently Medicaid-insured (24% v 11%), and more frequently rural residents (51% v 30%). During the last 30 days of life, compared with WH decedents, AIs had higher risks of hospital admissions (RR, 1.14 [1.07-1.22]), ICU admissions (RR, 1.24 [1.08-1.42]), >one ED visits (RR, 1.27 [1.09-1.47]), and in-hospital death (RR, 1.22 [1.06-1.40]). CONCLUSION: Indicators of inappropriate EOL care (hospital, ICU, and ED admissions) were notably higher during the last month of life for AI decedents with lung cancer. These findings highlight EOL care as an area where more interventions are needed to improve AI cancer care.


  • Shared Decision Making Interventions for Deprescribing in Older Adults With Polypharmacy: A Scoping Review

    by Soroush Fariman, Arman Arabshomali, Darshna Goordeen, Joshua D. Niznik, Homa Hemati, Jennifer Elston Lafata

    Background: Despite being integral to the deprescribing process, integration of shared decision making (SDM) into structured deprescribing interventions and its relation to patient outcomes remain understudied. Methods: We conducted a scoping review of PubMed/MEDLINE, Embase, Scopus, and PsycInfo (through September 2023) with a medical librarian's guidance. Studies of SDM interventions for deprescribing in older adults with polypharmacy were included. Two independent reviewers performed screening and data abstraction. An iterative narrative synthesis was conducted to categorize the core functions (purposes) and forms (specific activities) of the identified interventions, along with their measured outcomes, including SDM‐related outcomes. Results: Among 5402 retrieved records, 14 studies of 12 distinct interventions met the inclusion criteria. Studies were published between 2017 and 2023 and described a pilot implementation ( n = 3), randomized controlled trials ( n = 9), or patient interviews assessing perceptions regarding interventions ( n = 2). Most interventions ( n = 9) evaluated were specific to the outpatient setting and led by primary care physicians ( n = 6) or pharmacists ( n = 3). Two ( n = 2) were hospital‐based, involving pharmacists with nurse practitioners or physicians, and one ( n = 1) took place in nursing homes, led by nurses. Along with patient and medication identification ( n = 12) and SDM ( n = 12), common core functions included decision support ( n = 7), care coordination ( n = 5), coordinating follow‐up and monitoring ( n = 3), and family/caregiver involvement ( n = 2). Only 4 studies explicitly mentioned an SDM framework, the Three‐Talk Model ( n = 2), AHRQ SHARE ( n = 1), and the Collaborative Deliberation Model ( n = 1); only three ( n = 3) explicitly measured whether SDM occurred. The majority reported positive associations between the SDM interventions and medication use ( n = 6) and deprescribing behaviors ( n = 8). Conclusions: There is substantial variability in how deprescribing interventions incorporate SDM. Most studies do not empirically measure SDM. While SDM is associated with improved satisfaction and process of care outcomes, evidence regarding the impact of SDM‐informed deprescribing interventions and patient behavioral and health outcomes is inconclusive.


  • Open Access

    Diabetes medication management recommendations for older adults: A systematic review of the Western Pacific region

    by Darshna Goordeen, J Simon Bell, Youmna Elsedfy, Soroush Fariman, Shota Hamada, Yukari Hattori, Kate Wang, Majd Abu Al Shieh, Michael Nunan, Joshua D Niznik, et al.

    Aim: The Western Pacific region has the fastest aging population and 38% of the world's diabetes population. It is unknown to what extent medication management recommendations are included for older adults in type 2 diabetes (T2D) clinical practice guidelines (CPGs).Method: MEDLINE, Embase, Scopus, guideline‐specific registries and gray literature searches were performed in November 2024. Data were extracted on guideline characteristics and recommendations relevant to older adults, dementia, frailty, co‐morbidities associated with aging or end‐of‐life. Quality appraisal was performed using the AGREE II (Appraisal of Guidelines, Research and Evaluation) tool.Results: From the 37 countries and areas of the Western Pacific region, 16 CPGs were identified, of which 15 included 1–29 relevant recommendations. Thirteen CPGs recommended less stringent and/or individualized glycemic targets focused on reducing hypoglycemia for older adults. Five CPGs recommended individualized antihyperglycemic treatment choices. Seven CPGs included recommendations about de‐intensification/simplification of complex regimens. The quality of CPGs varied, with scope and purpose rated the highest.Conclusions: There was heterogeneity in the number of recommendations within CPGs; however, none comprehensively addressed the T2D medication management needs of older adults or those living with dementia, frailty or receiving end‐of‐life care. Collaboration between diabetes and geriatric societies as well as the assistance of higher‐income countries in helping those with less resource availability could provide a way forward to improving future CPGs. Geriatr Gerontol Int 2025; 25: 717–729.


  • End-of-life care quality for American Indians with cancer

    by Marc A Emerson, Lisa P Spees, Bradford E Jackson, Soroush Fariman, Joel Begay, Hayley N Morris, Ana I Salas, Christopher D Baggett, Tomi Akinyemiju, Ronny A Bell, et al.

    Background: American Indians experience disparities in cancer outcomes. Little is known about the quality of end-of-life care in American Indian patients with cancer. Methods: We retrospectively analyzed end-of-life care for North Carolina patients who died (decedents) diagnosed with any cancer between 2003 and 2018 using the Cancer Information & Population Health Resource. Measures of end-of-life care quality were informed by existing literature and included in-hospital death, hospice use, and other health-care utilization within the last 30 days of life. Associations between race and ethnicity and end-of-life outcomes were evaluated to estimate adjusted risk ratios (RRs). Because within-group heterogeneity can influence health outcomes and intervention effectiveness, we also evaluated associations among American Indian individuals only. Results: We identified 163 285 (1769 American Indian and 161 516 White) decedents. The majority (60%) of American Indian individuals lived in a geographic area characterized by non–federally recognized tribes. American Indian decedents had greater proportions of rural residence than White decedents (54.5% American Indian vs 30.4% White) and dual-Medicaid/Medicare enrollment (37.4% American Indian vs 17.7% White). Compared with White decedents, American Indian decedents had increased hospital admission (adjusted RR = 1.10, 95% confidence interval [CI] = 1.06 to 1.15), intensive care unit admission (adjusted RR = 1.21, 95% CI = 1.11 to 1.32), and more than 1 emergency department visit (adjusted RR = 1.31, 95% CI = 1.20 to 1.44) in the last 30 days of life. We observed statistically significant within-group variation in end-of-life care quality among American Indian patients. Conclusions: Structural barriers to care and rurality may contribute to lower-quality end-of-life care among American Indian decedents compared with White patients. High-quality, culturally appropriate end-of-life care will require a better understanding of care decision-making and access.